Cargando…
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody...
Ejemplares similares
-
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study
por: Muwonge, Richard, et al.
Publicado: (2020) -
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
por: Basu, Partha, et al.
Publicado: (2021) -
Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India
por: Bhatla, Neerja, et al.
Publicado: (2018) -
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
por: Sankaranarayanan, Rengaswamy, et al.
Publicado: (2016) -
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
por: Joshi, Smita, et al.
Publicado: (2023)